NIH-funded research R01 grant

Engineered B cells designed to deliver therapy directly in the gut

Official title: Engineered perturbations to define B cell entry, competition, and function in intestinal immunity and inflammation

Funded at Seattle Children's Hospital · NIH-11430087 · Data updated 2026-11-12

These researchers are testing a way to reprogram gut-homing B cells to deliver therapy right where inflammatory bowel disease occurs.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionSeattle Children's Hospital
NIH-funded
Lab location1 site (Seattle, United States)
Project startAugust 4, 2026
Project endJuly 31, 2031
Funding year2026
Award (this year)$911,271
NIH project number1R01AI201425-01
Project IDNIH-11430087 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates are individuals with inflammatory bowel disease (Crohn’s disease or ulcerative colitis) who may benefit from localized gut-directed therapies.

Less likely to help

Patients unlikely to benefit include those without IBD or whose disease is not gut-localized, or who cannot undergo potential future experimental procedures.

What this research studies

This project explores making special B cells that stay in the gut and release therapeutic proteins over time to treat inflammatory bowel disease. By engineering B cells to recognize gut bacteria, they aim to keep healing medicines localized in the intestine and reduce systemic side effects. The team plans to study how B cell activation and signaling steer these cells into durable antibody production in the gut lining. Results could lead to a new, targeted approach for managing inflammation with fewer off-target issues.

Why it matters

Potential benefit: If successful, patients with IBD might experience fewer systemic side effects and more effective control of gut inflammation.

How similar studies have gone: Previous work in targeted biologic delivery to the gut has shown promise in animal models, but human translation is still emerging.

Where this research is happening

  • Seattle Children's Hospital
    Seattle, United States
    Active

Researchers

  • Principal investigator: James, Richard Goff — Seattle Children's Hospital
  • Study coordinator: James, Richard Goff

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.